This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Antigenics brings in $26.1mm through private placement
10 Jan 2008
Antigenics (therapeutic vaccines for cancer and infectious diseases) raised $26.1mm through the private placement of 8.7mm common shares at $3 each (a 43% premium). Invus Public Equities led and was joined by Oracle Investment Management, other accredited investors, and Antigenics's CEO Dr. Garo Armen. Buyers also received ten-year warrants to purchase an additional 8.7mm common shares at $3 each, and unit warrants to purchase 8.7mm shares (with the same exercise terms) that would be triggered upon completion of a qualifying financial transaction within the next two years.
Private Investment in Public Equity
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?